Details werden geladen...
FDA Approves Roivant's LISRAYA As First And Only Targeted Therapy For Dermatomyositis | 27.08.26 | finanzen.at
(RTTNews) - Roivant Sciences Ltd (ROIV), a biopharmaceutical company, on Thursday received approval from the U.S. Food and Drug Administration (FD...
Ähnliche Seiten
FDA Approves Roivant's LISRAYA As First And Only Targeted Therapy For Dermatomyositis | 27.08.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/fda-approves-roivants-lisraya-as-first-and-only-targeted-therapy-for-dermatomyositis-1036500288
FDA Approves AbbVie's SKINVIVE For Neck Line Reduction | 16.06.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/fda-approves-abbvies-skinvive-for-neck-line-reduction-1036252891
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer | Hacker News
https://news.ycombinator.com/item?id=49451675
U.S. FDA approves first mRNA flu shot from Moderna
https://www.ctvnews.ca/health/article/us-fda-approves-first-mrna-flu-shot-from-moderna/
Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy | 19.08.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/sight-sciences-announces-fda-label-expansion-for-tearcare-dry-eye-therapy-1036474201